US National Institutes of Health advance cAd3-EBOZ and VSV-ZEBOV to Phase III trials

30 March 2015

The US National Institutes of Health (NIH) has announced that two Ebola vaccines appear safe, and will advance to Phase III testing.

The National Institute of Allergy and Infectious Diseases (NIAID) sponsored the trial, which examined the effects of cAd3-EBOZ, developed by GlaxoSmithKline (LSE: GSK) and the NIAID, and VSV-ZEBOV, developed by the Public Health Agency of Canada and licensed to NewLink (Nasdaq: NLNK) and Merck & Co (NYSE: MRK) on 600 people in a mid-stage trial in Liberia.

The NIH said that it recruitment will continue in the Phase II part of the study, and that enrolment will increase to around 1,500 people, partly to increase the percentage of women in the study. Currently only around 16% of participants are women, and those conducting the trial are aiming to ensure there are no gender-based differences in immune response or side effects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK